Showing 14 of 14 recruiting trials for “Angiosarcoma”
Intratumoral Vusolimogene Oderparepvec (VO) in Combination With Pembrolizumab for Angiosarcoma
👨⚕️ Varun Monga, MBBS, University of California, San Francisco📍 1 site📅 Started Jan 2026View details ↗
Pembrolizumab for Advanced Cutaneous Sarcomas Not Including Angiosarcoma
RecruitingNCT06715579 ↗
Cardiac Angiosarcoma International Registry
👨⚕️ Shushan Hovsepyan, MD, Immune Oncology Research Institute, Yerevan, Armenia📍 1 site📅 Started May 2025View details ↗
IO Combined With AI as First-line Treatment for Patients With Soft Tissue Sarcoma(TAIS)
Pembrolizumab Plus Lenvatinib in Unresectable Cutaneous Angiosarcoma Patients
A Study to Evaluate Safety, Tolerability and Preliminary Activity of AGX101 in Participants With Advanced Solid Tumors
RecruitingNCT06375941 ↗
Prospective Observational Study of Localized Angiosarcoma of Any Site: ProStars
👨⚕️ Elena Palassini, IRCCS Istituto nazionale Tumori - Milano📍 19 sites📅 Started Mar 2024View details ↗
RecruitingNCT06541652 ↗
A French Multicenter Observational Retrospective Study of Rare Primary Liver Cancers
👨⚕️ jean-charles nault, Pr, Federation Francophone de Cancerologie Digestive📍 40 sites📅 Started Mar 2024View details ↗
MASCT-I Combined With Doxorubicin and Ifosfamide for First-line Treatment of Advanced Soft Tissue Sarcoma
A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer
RecruitingNCT07432932 ↗
Precision Medicine Approaches for Neoadjuvant Therapy in High-risk Sarcoma Patients
Propranolol and Pembrolizumab in Advanced Soft Tissue Sarcoma Patients
Efficacy and Safety of Regorafenib as Maintenance Therapy After First-line Treatment in Patients With Bone Sarcomas
I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
👨⚕️ Laura Esserman, MD, MBA, University of California, San Francisco📍 42 sites📅 Started Mar 2010View details ↗
Get alerts when new trials open
Create a free account to follow conditions and receive trial notifications.
Create free account →